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ABSTRACT 
Obesity is a major health problem worldwide. It is preventable in theory, but in practice no 
country has been able to stop the development of increasing obesity. The only available 
treatment with sufficient long-term effect on weight loss and comorbid diseases is surgery. 
Bariatric surgery has increased over the last decades as several studies demonstrated long-
term weight-loss, dramatic effect on diabetes and other comorbid diseases and an effect on 
mortality. The introduction of laparoscopic surgery and refinements of surgical procedures 
with an overall reduction of postoperative complications and morbidity has also helped to 
enhance public perception of bariatric surgery. The aim of this thesis was to evaluate the 
positive effect of bariatric surgery on diabetes, and other potentially negative effects of 
surgery. 
As gastric bypass surgery became increasingly popular, several anecdotal reports suggested 
that these patients were overrepresented in alcohol treatment programs. In paper I we divided 
all patients who underwent bariatric surgery between 1980-2006 into two cohorts. One cohort 
consisted of patients that were operated with gastric bypass and the other consisted of patients 
operated with gastric banding or vertically banded gastroplasty, so called restrictive 
procedures. Data on inpatient diagnosis of depression, suicide attempt, alcohol and substance 
use disorders were retrieved from the National Patient Register. The main finding was that 
the risk for post-operative alcohol use disorders was elevated in the gastric bypass cohort 
compared to the restrictive cohort. 
In paper II we compared patients operated with primary gastric bypass in Sweden between 
2001-2010, with an age- and sex-matched control group that was sampled from the general 
population. The same outcome as in paper I was studied. In a subcohort we also analyzed the 
prescription pattern of antidepressants, benzodiazepines, hypnotics and sedatives and 
medication against alcohol dependence, before and after surgery. The main findings were that 
patients undergoing gastric bypass had a higher risk of preoperative diagnosis of depression, 
substance abuse and suicide attempts. After surgery the risk for all investigated diagnoses 
were elevated, including alcohol dependence. Prescriptions of benzodiazepines, hypnotics 
and sedatives, and medication against alcohol dependence increased after gastric bypass 
surgery. 
In paper III we used the Scandinavian Obesity Surgery Registry and the Prescribed Drugs 
Register to investigate the effect of gastric bypass surgery on diabetes type 2 treatment. 67 % 
of patients with diabetes treatment before surgery were without diabetes treatment 2 years 
after surgery and 61% after 7 years. In patients with a short duration of diabetes treatment, the 
surgery was even more effective. Less than 2 % of patients with prediabetes before surgery 
were on diabetes treatment during 7-year follow up, which is lower than in a control group 
from the general population. 
In 2010 we changed the surgical technique used for gastric bypass, from a technique where 
the mesentery was divided, to a technique where the mesentery was kept intact. In paper IV 
we compared the 2 techniques retrospectively regarding postoperative complications, more 
specifically leakage during the first 30 days and ulceration/stenosis in the anastomosis during 
the first 6 months. Both leakage and ulceration/stenosis were significantly reduced after the 
change of technique. 
In summary we demonstrate that gastric bypass surgery has a dramatic effect on diabetes, and 
also a diabetes preventive effect in non-diabetic patients. We show that the effect on diabetes 
is better if the surgery is performed early after diabetes onset. On the other hand, we found 
that patients seem to have a higher risk for postoperative alcohol abuse disorders after 
surgery. Finally, our last study on complications indicates that gastric bypass should be 
performed without division of the mesentery.  
Gastric bypass is a safe surgical method with good long-term effects, but patients must be 
informed about potential negative effects and possibly, patients with previous alcohol abuse 
should be operated with another method. 
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1 INTRODUCTION 
1.1 DEFINITION AND EPIDEMIOLOGY OF OVERWEIGHT AND OBESITY 
The standard classification of overweight and obesity is the Body Mass Index (BMI), which 
is calculated by taking the weight in kilograms divided to the height in meter squared (kg/m2). 
This ratio is a better measure for obesity than weight 
alone, since the person’s length is taken into consideration. 
BMI is not a perfect measure, as it does not directly assess 
body fat. A very muscular person could for instance have 
a high BMI without having excess body fat, but in most 
people it is a good indicator of the level of body fat. BMI 
is the classification used in most publications and research 
on this matter, even if other measurements are also 
available such as the waist-hip ratio and waist 
circumference. These measurements focus on abdominal 
obesity which is important since visceral fat is a predictor 
for obesity related comorbidity1. The disadvantage is that 
it is difficult to measure waist and hip circumference with 
precision, whereas BMI is easier to reproduce. 
Obesity is a growing problem in the world and the problem is no longer restricted to 
developed countries. The average BMI has risen dramatically worldwide between 1980-2013, 
both in developed countries and developing countries2. The worldwide prevalence of 
overweight and obesity rose by 27.5% in adults and 47.1% in children during this period and 
it is estimated that the number of overweight and obese persons in the world is about 2.1 
billion in 2013. In developed countries overweight seems to peak in men at the age of 55 
years, when two of three men are overweight and one in four obese. These numbers are 
worldwide and the situation varies a lot in different countries. In the United States 60% of 
adult women and 70% of adult men are overweight, and about one of three is obese2. 
1.2 CAUSES OF OBESITY 
The modern society is promoting the obesity epidemic by a general reduction in energy 
expenditure due to modern life-style3 in combination with an overconsumption of energy. 
Changes in global food systems, with more processed, affordable and effectively marketed 
food leads to overconsumption of energy-rich food, which is probably the most important 
factor for the obesity epidemic4-7. Even if summation of the input and output of energy is the 
most obvious and important factor in the explanation of the obesity epidemic, the 
development of obesity is a more complex process involving socioeconomic8,9, 
environmental7 and genetical factors, as well as gut microbiome10-12. In high-income 
countries obesity follows a clear socioeconomic gradient, with greater prevalence in more 
disadvantaged population groups9. On an individual level certain genes have been linked to 
obesity13, even if the exact mechanism are largely unknown. It also seems like some 
individuals have a gut microbial community more efficient at extracting energy from their 
diet and to deposit that energy in fat11.  
Table 1 BMI (kg/m2) 
(((kg/m2) Underweight <18.5 
Normal 18.5-24.9 
Overweight 25-29.9 
Obesity >30 
           grade I 30-34.9 
          grade II 35-39.9 
          grade  III >40 
Classification of overweight and 
obesity according to WHO guidelines 
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1.3 CONSEQUENCES OF OBESITY 
Obesity increases the risk of developing hyperlipidemia, hypertension, diabetes and sleep 
apnea14,15, all of which are independent risk factors for cardiovascular disease. Cardiovascular 
disease is one of the most common causes of disease related death worldwide and the risk 
factors are in a high degree related to lifestyle and therefore preventable16. Obesity is not only 
associated with cardiovascular risk factors16, there is also evidence of an increased risk of 
certain cancers17-19, pain from joints20 and overall mortality21 is higher among obese 
compared to normal weight persons. For example, one study estimate that white men between 
20 and 30 years with a BMI >45 had a 22% reduction of remaining life-span22. Other studies 
reveals an increased risk of depression23, and the Quality of Life is lower compared to non 
obese persons24,25. 
1.4 NON-SURGICAL TREATMENT OF OBESITY 
Treatments of obesity include lifestyle interventions, diets, physical activity, behavioral 
therapy, pharmacological therapy and surgery. Studies on non-surgical obesity management 
are difficult to compare since treatments are not standardized. There are many different diets, 
intervention programs with different intensity and behavioral therapies, and methods are also 
often used in combinations.  Changes in lifestyle are the logic treatment for obesity but even 
if certain individuals can achieve persistent weight-loss, the long-term results are 
discouraging. A large study with intensive lifestyle intervention in overweight and obese 
diabetes patients showed a moderate mean weight loss of 4.7% at 8 years26 and this seems to 
be comparable to other studies27. Studies on non-surgical obesity management in patients 
with prediabetes have shown that diabetes to some degree can be prevented, or at least 
delayed28,29. However, trials of non-surgical weight loss in obese participants have failed to 
demonstrate a benefit in terms of reduced mortality or decreased cardiovascular disease event 
rates29,30. There are some randomized studies that compare surgical with nonsurgical 
methods27,31-34 and all show that surgery is superior to non-surgical intensive interventions, 
this is also the conclusion in a recent review article showing that surgical treatments are 
significantly superior with more weight loss and greater effect on comorbid disease35. There 
are a few medical treatments for obesity, but many promising medical treatments have later 
been withdrawn because of adverse effects36. The treatments have modest effects on weight-
loss37, and some have side effects that are not well tolerated by patients which lead to 
discontinuation of treatment. In Sweden there are only a few listed medical treatments for 
obesity, orlistat, liraglutide and a newly registered combination therapy of naltrexone and 
bupropion (Mysimba). None of the drugs are frequently used in the clinical setting, since the 
treatments are expensive and not subventioned. Orlistat is an inhibitor of gastrointestinal 
lipase, which lead to excretion of 30% of ingested fat37. This treatment leads to a moderate 
weight-loss at the expense of diarrhea and other gastrointestinal side effects and only 10% of 
patients continue treatment more than 1 year, and less than 2% for 2 years38. Liraglutide is a 
glucagon-like peptide-1 (GLP-1) receptor analogue that increases postprandial satiety and 
reduces energy intake. It is administered by daily subcutaneous injections and the treatment 
indication in Sweden is diabetes. In higher doses it can be used as a treatment for obesity, but 
this treatment is not subventioned in Sweden.  A recent randomized study on patients with 
prediabetes show that liraglutide, in high doses, induces 4,3% weight loss difference when 
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compared to placebo39. The same study show that treatment could prevent or delay the 
development of diabetes in patients with prediabetes.  
1.5 BARIATRIC SURGERY 
Bariatric surgery increased rapidly in Sweden from the turn of the century, until the peak in 
2011 (Fig 1). This was driven by the results from large studies presenting significant effect on 
overall mortality and effect on several obesity related comorbidities, especially diabetes40-42. 
Another important factor is the more widespread use of laparoscopic surgery, which lead to 
shorter hospital stay and less morbidity for the patient43, and with experience also shorter 
operating times. The mean operating time of a gastric bypass in Sweden today is 60 min, 99% 
of the operations are performed laparoscopic and most patients leave hospital on the first or 
second postoperative day. Mortality is very low, with numbers around 0.05%44. The reason 
for decreasing volumes after 2011 is probably caused by a rebound effect after the rapid 
increase between 2007-2011.
 
Fig 1. Number of bariatric procedures performed annually in Sweden 1998-2016. Figure from SOReg annual 
report 201644, reprinted with permission. 
 
Bariatric surgery is not a single procedure, but rather a group of different operations that 
works by different mechanisms and have different effects on weight loss and comorbidity45.  
Unfortunately, they are sometimes evaluated as one group, which may underestimate the 
positive effect of surgery in the methods that have the best effects. This is also the reason that 
this type of surgery to some degree still struggle with its reputation since many of the older 
methods were associated with high complication rates and many needed revisional surgery46. 
For instance, the Swedish Obese Subject (SOS) trials which is the most important clinical 
trial comparing non-surgical treatment programs with surgical intervention is based on 
surgical methods that are not widely used today45.  
1.5.1 History of bariatric surgery 
The idea of surgery as treatment for morbid obesity is not new; already in 1952 a surgical 
procedure to produce weight-loss by resection of a part of the small intestine is described. 
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Many different methods have been tried since, and some procedures have made more impact 
on the evolution of bariatric surgery (Fig 2). The most relevant procedures are jejunoileal 
bypass (JIB), Roux-en-Y gastric bypass (RYGB), vertical banded gastroplasty (VBG), 
biliopancreatic diversion (BPD)/ duodenal Switch (DS), adjustable gastric banding (AGB), 
and sleeve gastrectomy (SG). Today RYGB and SG are the most popular procedures, while 
JIB and VBG are abandoned. 
 
Fig 2. Bariatric surgery procedures. Illustrations from Karra et al. Mechanisms facilitating weight loss and 
resolution of type 2 diabetes following bariatric surgery47. Trends in Endocrinology and Metabolism 21 
(2010) 337–344.  
JIB 
JIB, means that a large part of the small intestine is bypassed. It was performed widely in the 
1970:ies and this procedure had good effect on weight loss but also many severe side effects, 
such as diarrhea, liver insufficiency, electrolyte deficiencies, urolitihiasis and osteoporosis. 
Because of these side effects, many patients had their shunt reversed with subsequent weight-
gain48,49. This method is not in use today. 
RYGB 
The first version of the gastric bypass was published by Mason and Ito in 196750, inspired by 
the weight-loss seen after gastrectomy with the Billroth-II technique. The gastric bypass was 
further developed by others, and the first RYGB, similar to the procedure performed today, 
was published in 197751. This procedure has been further refined, for example with a smaller 
gastric pouch, and it is still performed today. 
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AGB and VBG 
The surgery changed in the 1980:ies, towards the principle of restrictive surgery were 
mechanical restriction was achieved by various gastroplasties. Several variations were tried, 
but in the end two popular techniques were widely used, AGB52 and VBG53. These 
procedures produced weight loss and effect on diabetes and other comorbid diseases54, and 
the more severe side effects that was seen with the earlier malabsorptive surgery were 
eliminated. VBG was the most popular procedure in Sweden in the 1980:ies and 1990:ies. It 
has now been abandoned due to poor weight loss, weight-regain and complications such as 
band erosion and vomiting, and many of those patients have later undergone revisional 
surgery46,54. GB is also abandoned in Sweden, because of long-term complications similar to 
those in the VBG and high revision-rates 55,56, but GB is still performed in some countries.  
BPD/DS  
The BPD/DS is the most potent operation against morbid obesity57,58, but it also have more 
complications than RYGB and SG, thus limiting its use in clinical practice57,59,60. The 
complications and side effects are similar to, but not as severe as, the JIB. The advantage 
compared to the JIB is that no intestinal segment is left blind, thus preventing bacterial 
overgrowth. BPD/DS is mainly used in super obese patients, sometimes as a 2-step operation 
with the first procedure being a SG. This is a technically demanding procedure compared to 
RYGB and SG, and only 1-2% of bariatric procedures are performed with this technique. 
SG 
The SG is basically a gastroplasty where the stomach is divided longitudinally, forming a 
long narrow tube. It was originally described as a step in the DS, but is now being performed 
as a single procedure. This procedure is today the most popular procedure in the United 
States, and constitute about 50% of bariatric procedures from 201461. SG produce good initial 
results on weight-loss and comorbid diseases, but long-term data are still lacking. It still 
remains unclear if this procedure will have the same problem as other gastroplasties with 
weight regain over time.  
Current situation 
RYGB has been the most common operation during the past 15 years. In 2010, 97.5% of 
bariatric surgery procedures in Sweden were performed with RYGB, while SG has become 
increasingly popular during recent years. 2016 approximately one third of the operations in 
Sweden was SG44. The same tendency is seen in other parts of the world and today the SG is 
the most commonly performed procedure internationally to achieve weight-loss62, despite 
limited long term results (Fig 3). 
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Fig 3. Trends in bariatric surgery procedures worldwide. Figure created using data from Angrisani et al 
Bariatric Surgery Worldwide 2013. Obes Surg 201363 and Bariatric Surgery and Endoluminal Procedures: 
IFSO Worldwide Survey 2014. Obes Surg 201764. 
1.5.2 Mechanisms of bariatric surgery 
Historically weight loss after bariatric surgery has been explained by two different 
mechanisms, restriction and malabsorption of calories. Some methods have been designated 
as restrictive procedures, for example different gastroplasties, and some methods 
malabsorptive procedure, for example JIB. RYGB has been viewed as a combined technique 
with the small gastric pouch as a restrictive component and the bypass of a part of the 
proximal small intestine as a malabsorptive component. Today we know that the mechanisms 
are more complex than this65,66. It is true that one of the mechanisms by which weight loss is 
achieved is of course a restriction of calorie intake67. The classic explanation has been that 
patients eat smaller volumes due to a small gastric pouch, and that the uptake of consumed 
calories is reduced when a part of the small intestine is bypassed. However, today we know 
that more complex mechanisms involve changes in gut peptide release66,68-72, changes in gut 
microbiome73,74 and changes in bile flow among other effects75 (Fig 4).  
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Fig 4. Schematic presentation of the physiological mechanisms that underlie weight loss and glycemic 
improvements after gastric bypass surgery. Figure from Miras et al.65, reprinted with permission.  
The effect on diabetes is remarkable and seen within days or weeks after surgery, before 
weight loss occurs. This effect is not yet exactly understood but theories involve the hindgut 
hypothesis and the foregut hypothesis. The hindgut hypothesis has been used to describe that 
the effects of some bariatric operations result from enhanced nutrient delivery to the distal 
intestine, accentuating secretion of anorexigenic and antidiabetic peptides. The foregut 
hypothesis suggests that surgical exclusion of nutrients from the proximal small intestine 
exerts antidiabetic and possibly weight-reducing effects76. 
The most investigated hormones are GLP-1, peptide YY (PYY) and ghrelin, which all have 
been suggested to play a role in weight-loss after RYGB71,77,78. GLP-1 and PYY is secreted 
by the L cells of the small bowel, with higher concentrations in the distal ileum. GLP-1 and 
PYY levels increases soon after RYGB and their gastrointestinal properties include delayed 
gastric emptying, reduction of hunger and increased sensation of satiety79. GLP-1 inhibits 
glucagon release and acts on the pancreas to secrete insulin. If these hormones are blocked, 
the appetite returns, indicating that they play an important role in the weight-loss after 
surgery71,77.   
Ghrelin is a peptide that stimulates appetite and was initially thought to be important in the 
weigh-loss after RYGB, since early studies showed a decrease in ghrelin levels after surgery. 
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Other studies have not been able to show the same results and the role of ghrelin remains 
unclear80. 
1.5.3 Bariatric surgery candidates 
Standard criteria for bariatric surgery is BMI > 40, or BMI >35 with some comorbidity 
correlated to obesity. Other conservative methods should be tried before in most cases.  
Characteristics of bariatric surgery candidates 
Patients presenting for bariatric surgery differ from the general population on other measures 
than BMI. Generally the patients have lower education and socioeconomic status81, they also 
have more obesity related diseases and more psychiatric morbidity. In Sweden, 14 % of the 
patients have preoperative treatment for diabetes, 25% for hypertension, 10% for 
hyperlipidemia and 10% for sleep apnea. Average BMI is 42 kg/m2 in RYGB patients and 
slightly lower in SG patients44. 
Psychiatric morbidity in bariatric surgery candidates 
Bariatric surgery candidates have higher rates of mood and anxiety disorders than the general 
population before surgery82-84. In an Italian study, almost 40% of the bariatric surgery 
candidates had a lifetime history of an Axis I disorder. About one fifth of the sample 
presented with a current Axis I disorder and the same percentage had a personality 
disorder82. Even higher rates of Axis I disorders were found in an American preoperative 
survey where patients reported a lifetime history of 66%, and 38% met diagnostic criteria at 
the preoperative evaluation83. These studies are small but results are confirmed in larger 
studies. In the longitudinal assessment of bariatric surgery (LABS) study, an American 
multicenter study including more than 2000 patients, about 30% of the patients reported at 
least mild depressive symptoms before surgery and 35% used antidepressant medication84.  
 
1.6 ROUX EN Y GASTRIC BYPASS  
1.6.1 Surgical technique 
RYGB is performed laparoscopically if there is no contraindication. The procedure is 
commonly performed by the initial creation of a small gastric pouch, followed by the creation 
of a Roux-limb. This is traditionally accomplished by transection of the proximal jejunum 
about 30 to 50 cm distal to the ligament of Treitz, followed by division of the jejunal 
mesentery. A gastro-entero anastomosis (GE) is constructed by approximation of the distal 
tip of the transected jejunum to the small gastric pouch, which is then anastomosed together. 
The Roux-en-Y reconstruction is completed by the creation of an entero-entero anastomosis 
(EEA) between the proximal, or biliary, end of the transected jejunum and the Roux-limb, 
typically about 100 cm distal to the GE85. This technique will be referred to as Divided 
Mesentery Laparoscopic RYGB (DM-LRYGB). 
As with most procedures there are numerous variations of the basic RYGB technique, and 
those variances can of course affect the end result. For example, the Roux-limb can be 
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brought to the gastric pouch in both an antecolic and retrocolic fashion, the GE can be 
constructed with a circular or straight stapler, or even completely hand-sewn. Other things 
that might differ between different centers are the length of the roux limb, the size of the 
gastric pouch and if the mesenteric defects are closed or not and the perioperative routines.  
A slight modification of RYGB, which today is standard in Sweden, creates an antecolic 
Roux-en-Y limb by first bringing a proximal jejunal loop up to the gastric pouch to create a 
side-to-side GE, without division of the mesentery. Subsequently, the EEA is created and the 
Roux-en-Y construction is completed by the division of the jejunal loop between the GE and 
the EEA86. This technique will be referred to as Intact Mesentery Laparoscopic RYGB (IM-
LRYGB) (Fig 5). 
 
Fig 5. Illustration of the Laparoscopic Roux-en-Y Gastric Bypass technique with intact mesentery (IM-LRYGB). 
Illustration from Olbers, T et al. Laparoscopic gastric bypass: development of technique, respiratory function, 
and long-term outcome. Obesity Surg 2003. 13(3), 364–370. Reprinted with permission. 
  
1.6.2 Positive effects of RYGB surgery 
RYGB has many positive effects; one of the obvious is long-term weight loss. The weight 
loss itself is important, but even more important is the effect on comorbid diseases and the 
reduced mortality40,42. Non-surgical interventions to achieve weight-loss have so far been 
unable to show an effect on mortality, which in some way is the ultimate endpoint. Puzziferri 
et al87 did a review of the literature and the average excess weight loss 2-years after RYGB 
was 65.7%, diabetes remission rates of 66.7% and remission of hypertension of 38.2%. 
RYGB also has an effect on hyperlipidaemia41,87, sleep apnea88, reduced pain from joints and 
positive effect on life quality89.  
Effect on weight loss 
RYGB is a procedure that produces a rapid weight loss and most of the weight loss occurs in 
the first year after surgery41. Initial weight loss is about 25-35%34,45 of total body weight or 
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up to 80% excess weight loss (EWL)90. Even if the patients gain some weight over time, 
long-term effects on weight is good with almost 30% persistent reduction of body weight 
after 5 years27,45 and 60% EWL after more than 10 years91. This is not even comparable to 
other non-surgical means of weight-loss, where the most efficient studies report 5-
10%27,31,33,34 weight loss with a combination of medications and intensive lifestyle 
interventions. Other studies report no long-term weight loss at all41. The Swedish Obesity 
Study (SOS), which is one of the most cited studies in bariatric surgery, present a sustainable 
weight loss of about 30% of the total body weight92. The same study shows that the restrictive 
procedures, GB and VBG doesn´t result in the same weight loss as RYGB. The control group 
receiving conventional treatment (non-surgical) in the same study did not show any weight 
loss at all during follow-up. Data from SOReg show that the RYGB produce more weight 
loss than SG44, which is also supported by published studies90,93,94. 
 
Fig 6. Weight loss after bariatric surgery in Sweden. Figure created with data from SOReg annual report 
201644. 
Effect on diabetes 
RYGB has a dramatic effect on diabetes 32,45,81,87,95-99. Many studies present an initial diabetes 
type 2 remission of up to 70%41,98, depending on which criteria’s that are used to define 
remission. There are many studies with short follow-up, a recent study however present 5 
year data with a diabetes remission rate of 54%97. The SOS study presents 10 year data with 
diabetes remission of 36%41. It is important to notice that most of the patients in the SOS-
study were treated with VBG and GB, procedures we know have an inferior effect on 
diabetes87. Studies including only RYGB patients demonstrate long-term remission in up to 
60%91,98. Remission of diabetes with conservative treatment on the other hand is very low 
and all studies comparing surgery with intensive lifestyle interventions combined with 
medical therapy shows that RYGB has superior effect27,31-34,96,98,100. 
Except for the extreme effects on diabetes, RYGB also seems to prevent against the 
development of diabetes in obese patients95,101.  
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Because of the remarkable effects of RYGB surgery on diabetes, it is discussed whether 
surgery should be considered in patients with diabetes even with BMI <35, or even <30 in 
drug-refractory diabetes. Several studies have been performed with good effect on diabetes in 
non-obese patients, even if the effect is not as obvious as in obese patients102,103. So far, 
metabolic surgery is not performed routinely in non-obese patients with diabetes type 2, but it 
is performed in many countries on patients with BMI 30-35 with diabetes. . 
Effect on other cardiovascular risk factors and disease 
Although the effect on weight and on diabetes is the most eye-catching, RYGB also have an 
effect on other cardiovascular risk factors such as sleep apnea88, hypertension41,87,98 and 
hyperlipidaemia41,87. As expected, bariatric surgery doesn´t only reduce risk factors for 
cardiovascular diseases, it also has proven effects on actual cardiovascular diseases such as 
myocardial infarction and stroke81,92, and is also effective in reducing cardiovascular 
deaths42,92. 
Effect on cancer 
Obesity is a risk factor for certain cancers, such as colon, breast (in postmenopausal women), 
endometrium, kidney, esophagus (adenocarcinoma), gastric cardia, pancreas and 
gallbladder18,19,104-107. Before obesity surgery arrived there were no studies proving that 
weight loss would reduce the risk for cancer, simply because it was too hard to reach 
significant weight loss. With obesity surgery we can now study the cancer preventive effects 
on patients with significant and persistent weight loss. The SOS study has shown that 
bariatric surgery reduces cancer incidence in obese women, but could not show the same 
effect in men108. Other large studies show a significant reduction in both cancer incidence and 
cancer mortality after bariatric surgery109,110. These changes are probably related to the 
weight loss and not to the surgery itself. 
Effect on mortality 
The SOS study has shown that bariatric surgery reduces overall mortality compared to obese 
control subjects40, this important finding is supported by other studies42,111. In a recent review 
article the authors concluded that bariatric surgery patients had significantly reduced long-
term all-cause mortality when compared to severely obese non-bariatric surgical control 
groups111. They also had reduced cardiovascular-, stroke-, and cancer-caused mortality 
when compared to severely obese non-operated controls.  
On the contrary, non-disease related mortality such as accidents and suicides seems to be 
elevated amongst the patients that have surgery42,111,112. 
Effect on Health Related Quality of Life and depression 
Obesity is typically associated with poorer Health Related Quality of Life (HRQoL)113. The 
HRQoL is improved after surgery57,89,90,114-116, and seems to be correlated to weight-loss, with 
the highest scores 1-year after surgery when maximum weigh-loss has occurred. In the 
weight-regain period there seems to be a slight deterioration even if long-term effects 
persist116. The Quality of Life seems to improve most in physical aspects, whereas some 
studies have been unable to show improvement in the psychosocial aspect of Quality of 
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Life117. The reported effects on mood and anxiety disorders after RYGB are a bit conflicting. 
Thirtysix percent of the patients in a mixed bariatric surgery cohort presented with depressive 
symptoms before surgery, and after an initial improvement, the same amount of patients had 
depressive symptoms 7 years after surgery118. Another study presented improvement of Axis 
I disorders from 30.2% preoperatively to 18.4% at three-year follow up. Other studies also 
show an improvement after surgery, even if there seems to be deterioration in improvement 
after the first postoperative year84.  
 
1.6.3 Negative effects of RYGB surgery 
Patients undergoing RYGB often have preoperative risk factors for complications, such as 
severe obesity, diabetes and other comorbid diseases. As after all surgical procedures there is 
a risk for general complications such as deep vein thrombosis, pulmonary embolus, urinary 
tract infection, pneumonia and complications related to anesthesia. Complications more 
correlated to the procedure itself is leakage in the anastomosis, ulceration and stenosis in the 
anastomosis, small bowel obstruction, internal herniation, ventral hernias, abdominal pain, 
dumping and anemia. Generally, the complications after RYGB have decreased with time 
and the perioperative mortality is very low.  
Leakage 
The most feared surgical complication after RYGB is leakage, usually occurring in the GE. 
Leakage is usually obvious in the first postoperative days and early symptoms include 
epigastric pain and tachycardia. Historically leakage occurs in 0,6-4,4%119 of patients, but 
large later studies present leakage rates closer to 1%120 which is similar to leakage rates 
presented in SOReg44. Leakage is most often treated with surgical exploration, drainage and 
sometimes, endoscopic stenting121. 
Stenosis and ulceration in the anastomosis 
Symptoms of stenosis include dysphagia, nausea and vomiting. Reported rates of stenosis 
after RYGB vary greatly in the literature, variations might depend on different surgical 
technique, length of follow-up and definition of stenosis for example. Stenosis is much more 
usual after circular stapling of the anastomosis122,123and maybe also with an antecolic roux-
limb124. Linear stapling is the most common technique and many studies report stenosis rates 
of about 5-10% with linear stapling 125-128. Stenosis is treated with endoscopic dilation, 
sometimes repeated, and surgical intervention is seldom required.125,127,128 Dilation is 
generally safe, but perforation is a potential threat. Ulceration at the anastomosis is another 
usual complication. Incidence of symptomatic ulceration differs between studies and a review 
of the literature found an average incidence of ulceration of 4.6%, with a variation between 
0.6% and 25%129. Stenosis might actually be the result of an ulcer healing with stricture. One 
study performed routine endoscopy 1-month after surgery and found ulceration in 12% of 
patients, and in 40% of those with ulceration there was also some degree of stenosis130. 
Reasons for ulceration are probably multifactorial. Helicobacter Pylori, smoking and diabetes 
are risk factors131,132, and Proton Pump Inhibitors have a prophylactic effect133-135. Tension 
  13 
and ischemia at the anastomotic site are other factors that could increase the risk for 
ulceration. Most ulcers heal with PPI treatment and surgical revision is unusual 134. 
Internal herniation 
Internal herniation (IH) is a common complication after RYGB. In general it is seen after a 
substantial weight has been lost, usually at least 1 year after surgery. It can occur several 
years after surgery. IH can cause bowel obstruction and symptoms include intermittent 
abdominal pain, vomiting and abdominal swelling. Sometimes the patients present with 
acute symptoms, and other times they present with more chronic intermittent symptoms. In 
severe cases IH can cause strangulation of the small bowel with subsequent bowel gangrene 
136. Since follow-up after surgery generally decreases after the first few years, late 
complications can be underestimated. Some studies with longer follow-up report IH in 10-
16% of patients137-139. Internal herniation can occur in the Petersen defect, located in the 
mesenteric defect under the roux limb or in the mesenteric defect at the EEA site. If the 
roux limb is brought up to the gastric pouch in a retrocolic way there is also the possibility 
of herniation in the mesenteric defect of the colon140.  
IH rates have been proposed to be lower when performing IM-LRYGB, possibly by 
reducing the size of Petersen´s defect. A retrospective study of 1400 patients found IH in 
only 0.2 % after IM-LRYGB even if the mesenteric defects were left open 141. This seem 
very low and the follow-up time was short, other case series also show higher rates of IH at 
a later time point 137. A retrospective comparison of DM-LRYGB with IM-LRYGB, show a 
decrease in IH in favor for the IM-LRYGB, but these results must also be interpreted with 
caution since the mesenteric defects was closed in the IM-LRYGB and not in the DM-
LRYGB142. A recent randomized study found IH in 10% of patients operated with IM-
LRYGB143 without closure of the mesenteric defects. There has been a discussion whether 
or not the mesenteric defects should be closed or not, and even if most surgeons have 
advocated closure of the defects evidence have been lacking. However, the same 
randomized study, show that internal herniation can be reduced from about 10% to 5% if 
the mesenteric defects are closed143.   
Dumping 
Dumping syndrome, a common complication of RYGB, can be divided into early and late 
dumping symptoms.  Early dumping occurs within 1 h after a meal, when the rapid 
emptying of undigested food into the small intestine triggers fluid shifts into the intestinal 
lumen and release of gastrointestinal hormones. Common symptoms include abdominal 
pain, nausea, diarrhea, and vasomotor symptoms such as fatigue, flushing, palpitations, 
perspiration, tachycardia and hypotension144 (Fig 7). 
 Late dumping occurs 1 to 3h after intake of carbohydrates, caused by a hyperinsulinemic 
response resulting in hypoglycemia. Typical symptoms of hypoglycemia are fatigue, 
weakness, confusion, perspiration, palpitations, tremor and irritability144. 
Dumping symptoms after RYGB vary from mild to severe, and since the spectrum of 
symptoms and severity is broad, the reported prevalence after RYGB varies between 
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different studies144-146. A recent study report that 93,4% of patients have no or mild 
symptoms, and only 1,4% have severe symptoms after RYGB 145. Dumping syndrome can 
be troublesome, but most of the times symptoms can be reduced by avoiding carbohydrate 
dense meals and soda, not drinking at the same time as eating and to eat slowly144. 
 
Fig 7. Physiology and symptoms of dumping syndrome. Figure from Van Beek et al. Obes Rev. 2017144. 
Excess skin 
Massive weight-loss leads to excess skin in almost all patients. In a questionnaire study 
84% of RYGB patients reported problems with surplus skin 147.The abdomen, upper arms, 
medial thigh and breast were the sites where most patients had problems. In the same study 
46% of patients reported that the excess skin cause eczema, fungal infections and lesions 
below the abdomen, the breast or in the groin 147. 
Abdominal pain 
Chronic abdominal pain after RYGB is a complication that is not unusual148, 5-years after 
surgery about one third of patients report some form of chronic abdominal pain. Some of 
those patients had symptoms that could be related to a specific complication, but in most 
patients no obvious reason was detected149. Thorough examination of these patients to 
exclude treatable conditions such as cholelithiasis, ulcerations or internal herniations is 
vital, but sometimes no diagnose can be found. 
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 Suicide 
Even though some studies suggests an improvement in depression and HRQoL after surgery, 
for some reason surgery increases the risk of suicide and death by accidents42,111,112,150. The 
reason for this is not established but one theory is that bariatric surgery, and especially RYGB 
could lead to alcohol and substance abuse151-155. 
Alcohol abuse disorders 
Patients undergoing RYGB surgery seem to be more prone to develop alcohol use disorders 
than those undergoing restrictive procedures151,152,156, which might be due to the altered 
uptake and metabolism of alcohol seen after RYGB157-159. 
 
Fig 8. Peak alcohol concentration before and after gastric bypass surgery. Figure from Woodard et al. J Am 
Coll Surg 2011159.  
 
It is known that the time of gastric emptying affects the absorption of alcohol160. Ethanol 
undergoes a first pass metabolism in the stomach and liver. Gastric first pass metabolism of 
ethanol primarily depends on the activity of gastric alcohol dehydrogenase (ADH). In 
addition, the speed of gastric emptying may modulate both gastric and hepatic first pass 
metabolism of ethanol160. The small gastric pouch with rapid emptying to the small intestine 
after RYGB is likely to reduce the first pass metabolism exerted by gastric ADH. One study 
gave the same amount of alcohol to RYGB patients, before and after surgery, and there was a 
higher and more rapid peak alcohol concentration after surgery159. This means that the 
patients more easily get drunk from small amounts of alcohol after surgery, possibly 
triggering alcohol abuse. When the same test was performed on GB patients there was no 
such difference161. It has also been shown that RYGB patients have higher risk of being 
admitted for alcohol abuse than patients operated by restrictive methods151. One study from 
the United States showed that 16% of patients seeking bariatric surgery were problem 
drinkers162, and a large multicenter study from the US reported significantly higher 
prevalence of hazardous alcohol use, symptoms of alcohol abuse/dependence, and fulfilled 
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criteria for alcohol abuse/dependence at 2-year follow-up after RYGB surgery, compared to 
the first postoperative year and prior to surgery156. 
Most studies regarding alcohol and substance abuse are based on interviews and 
questionnaires156,163-165, and some have problem with low participation rate, small sample size 
and retrospective collection of data163,165. There is also a reason to consider that those with 
ongoing abuse could have a lower participation rate, leading to biased results.  
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2 AIM 
2.1 GENERAL AIM 
Our general aim was to characterize positive and negative aspects of gastric bypass surgery. 
2.2 SPECIFIC AIMS PAPER I-IV 
Paper I 
The aim in paper I was to investigate if the risk for psychiatric disorders including alcohol 
and substance abuse is increased after RYGB surgery. Further to investigate if there is a 
difference between RYGB and other restrictive surgery methods. 
Paper II 
The aim in paper II was to investigate if the risk for psychiatric disorders including alcohol 
and substance abuse is higher in RYGB patients compared with general population 
comparators, before and after RYGB.  
Paper III 
The aim in paper III was to determine remission rates of diabetes treatment after RYGB 
surgery in diabetic patients, and to determine if surgery protects against future diabetes 
treatment in non-diabetic patients. 
Paper IV 
The aim was to determine if there was a difference in anastomotic complications between 2 
different techniques of RYGB, where the mesentery was either divided or kept intact. More 
specifically the aim was to determine if ulceration and stenosis in the anastomosis during the 
first 6months, and anastomotic leakage during the first 30 days, were reduced after changing 
the technique. 
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3 PATIENTS AND METHODS 
 
3.1 INFORMATION SOURCES 
All Swedish citizens have a personal identification number (PIN) that allows linkage between 
different registers and this makes it possible to get information about large nationwide 
cohorts of patients.  
In Sweden there are a number of different registers that contains information about education, 
health care diagnosis, death cause, data on prescribed drugs etc., below is a description of the 
main registries that have been used in this thesis project.  
3.1.1 Register of the Total Population 
This register contains information on all Swedish residents and it is held by Statistics Sweden 
(SCB). It includes a number of variables, for example PIN, sex, age, name, address, marital 
status, citizenship, immigration, emigration and date of death166. Data from this register is 
used in paper I-III 
3.1.2 The Cause of Death Register 
The National Board of health and welfare (NBHW) holds this register and it contains dates of 
all deaths among Swedish citizens from 1961 and cause of death in almost all cases. About 
1% have no cause of death registered167. Data from this register is used in paper I-III. 
3.1.3 Prescribed Drugs Register 
The nationwide Swedish Prescribed Drug Register (PDR)168 was established in 2005 and 
includes all dispensed prescription drugs classified according to the World Health 
Organization Anatomical Therapeutic Chemical (ATC) classification system. The register 
does not include medications administered in hospital. Data from this register for example 
include patients’ age, sex, personal identification number, date of prescription and dispensing, 
the practice that has prescribed the drug and the profession of the prescriber. 
Data from this register is used in paper II and III. 
3.1.4 The National Patient Register 
The National Patient Register (NPR), is a nationwide register held by NBHW, to which all 
hospitals are obliged to report. It contains dates of admission and discharge as well as ICD-
codes for diagnoses and surgical procedures from 1964. The inpatient part of NPR attained 
national coverage in 1987 and since then covers nearly 100 per cent of all hospital 
admissions. From 2001 NPR also contains information about outpatient visits in specialized 
health care, with a coverage rate of about 75% during the first years and around 96% today. 
169 Data from this Register was used in paper I-III. 
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3.1.5 The Scandinavian Obesity Surgery Registry  
The Scandinavian Obesity Surgery Registry (SOReg) is a nationwide, prospective quality 
registry of bariatric surgery started in 2007. The register has been estimated to cover about 
99% of all bariatric surgery procedures in Sweden, but the numbers are lower at follow-up 
(listed below in parentheses). Data in SOReg include information about type of procedure, 
weight, complications, medications and blood-chemistry. Data is registered before surgery 
and then 6 weeks (94,8%), 1 year (82%), 2 year (59%) and 5 year (49%) after surgery. 43 
surgical units report to SOReg44 . 
Data from SOReg has been used in paper III. 
3.1.6 Internal Quality Registry held at Danderyd Hospital 
Data on all bariatric procedures have been held at Danderyd Hospital since 1995 for quality 
assurances. The Internal Quality Registry (IQR) includes information about date of surgery, 
type of procedure, surgeon, complications as well as weight data. Data from this registry was 
used in paper IV. 
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3.2 COHORTS 
All studies are retrospective studies using data from the different registries. In paper I and II 
we used the NPR to identify obesity surgery patients, by using the Swedish version of the 
Classification of Surgical Procedures (NOMESKO) codes related to bariatric surgery 
(4751, 4753, JDF00, JDF01, JDF10, JDF11, JDF20, or JDF21) with a confirmatory code of 
obesity from the ICD classification system (277.99, 259X, 278A, E66.0, E66.1, E66.8, or 
E66.9). In paper III we used SOReg data to gather our cohort of gastric bypass surgery 
patients. In paper IV we used data from the internal quality registry (IQR) at Danderyd 
Hospital to identify our study cohort.  
  
Table 2 Paper I Paper II Paper III Paper IV 
Surgery 
method 
RYGB Restrictive 
(VBG/GB) 
RYGB RYGB DM-
LRYGB 
IM-
LRYGB 
Patients 4161 6954 16755 22047 1016 1404 
Controls NA 167550 matched controls 
from the general 
population 
175138 matched controls 
from the general 
population 
NA 
Main Data 
sources  
NPR NPR, PDR SOReg, PDR, NPR IQR 
Study period 1980-2006 2001-2010 2007-2012 2006-2015  
Outcome 
measure 
Psychiatric comorbidities Psychiatric comorbidities, 
Prescriptions 
Diabetes medication Complications  
NPR = National Patient Register; PDR = Prescribed Drugs Register; SOReg = Scandinavian Obesity Surgery Registry; IQR = 
Internal Quality Register 
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3.3 STUDY DESIGN AND STATISTICS 
3.3.1 Paper I 
In this retrospective cohort study the RYGB cohort was compared to the restrictive cohort 
(VBG/GB), regarding inpatient diagnosis of depression, substance abuse, alcohol abuse and 
suicide attempts before and after surgery.  
The number of hospitalizations before and after surgery, according to the ICD-8, ICD-9, or 
ICD-10, for the following diagnoses was gathered from the NPR: depression (ICD-8 and 
ICD-9: 300 and 790.2; ICD-10: F32-F39), substance abuse (excluding alcohol abuse) (ICD-
8 and ICD-9: 304; ICD-10: F11- F16), attempted suicide (ICD-8 and ICD-9: E95 and E98; 
ICD- 10: X60-X84 and Y10-Y34), and alcohol abuse (ICD-8 and ICD-9: 303; ICD-10: 
F10). 
Incidence Rate Ratios (IRR) were calculated preoperatively. The person was considered as 
having an event if the diagnosis in question was detected in the NPR from the age of 18 
years to the date of surgery.  
In the analysis of postoperative morbidity, a person was considered to have an event the 
first time the person was diagnosed in the NPR after surgery. Person-time at risk was 
calculated. Patients were followed until death, emigration or the end of the study (31dec 
2006). In Cox proportional hazards regression analysis, the postsurgical hazard ratio (HR) 
was adjusted for age at surgery, preoperative occurrence of the same diagnosis, 
socioeconomic position, and education level. 
3.3.2  Paper II  
In this retrospective cohort study, the surgery cohort consisting of only primary RYGB 
patients >18 years of age, was compared with a matched control group from the general 
population regarding the same inpatient diagnosis as in study 1. 
Each RYGB patient was matched to ten age- and sex-matched controls, selected randomly 
from the general population. Each member of the reference group was assigned a pseudo-
surgery date corresponding to that of the case participant, resulting in the same before and 
after observation periods for the matched individuals.  
Preoperative and postoperative incidence rate ratios (IRR) were calculated. The 
preoperative person-time at risk was calculated from the age of 18 years to the date of 
surgery/pseudo-surgery or until the person had an event for the first time. The person was 
considered to have an event when the diagnosis in question was detected in the NPR.  
In the analysis of postoperative morbidity, the patient was considered to have an event the 
first time the diagnosis was detected in the NPR; person-time at risk was calculated 
accordingly. The follow-up time was from date of surgery/pseudo-surgery until date of 
death, emigration or the end of the study, whichever came first. Post-surgery HR was 
calculated with the Cox regression model, adjusting for age, sex, preoperative diagnosis 
(alcohol use disorder, substance use disorder, depression, suicide attempt), socioeconomic 
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status and educational level.  
In a subgroup of patients, prescribed drug dispensation data were collected from the PDR 
for the following ATC group of drugs: alcohol dependence (N07BB), benzodiazepines 
(N05BA), hypnotics and sedatives (N05C), and antidepressants (N06A). This subgroup 
included all patients from the main cohort who had surgery between July 2006 and March 
2008. This cohort was used to determine drug use before and after surgery and the time 
period was chosen because we wanted to have prescription data from the PDR for these 
patients at least 1 year before surgery and 4 years after surgery. 
In the analysis of drug prescriptions, the percentage of persons who had at least one 
prescription filled per year was calculated for each drug. A Poisson regression with 
generalized estimating equations to account for within-individual correlation due to 
repeated measurements to estimate relative risks (proportions), confidence intervals and P 
values was performed. Wald χ2 tests were used for analysis.  
3.3.3 Paper III 
In this retrospective cohort study, we linked SOReg data with the NPR and the PDR. Patients 
without baseline HbA1c were excluded as well as patients with a diagnosis of diabetes type 1, 
without a diagnosis of diabetes type 2, in the NPR. 
From these patients we created 2 different cohorts, called the remission cohort and the 
incidence cohort based upon diabetes treatment status in the last year before surgery. 
The remission cohort consists of patients with at least one prescription of diabetes drugs the 
year before surgery. This cohort was used to study remission of diabetes drug treatment after 
surgery. 
The incidence cohort consists of patients without any history of diabetes drug treatment in the 
PDR or diabetes diagnosis in the NPR. From this group, we also excluded patients with a 
preoperative HbA1c levels indicating diabetes. This cohort was used to study incidence of 
diabetes treatment after surgery in patients without diabetes at baseline. 
The annual proportion of diabetes drug treatment in the remission cohort was calculated for 
up to 5 years preoperatively and up to 7 years postoperatively.  
For patients in the incidence cohort the prevalence of diabetes drug treatment, for each 1-year 
interval from the date of surgery up to 7 years after surgery, was calculated for the total 
surgery group as well as for the subgroups with euglycemia and prediabetes. 
For the incidence cohort, incident use of pharmacological diabetes treatment was also 
analyzed using survival analysis. Adjusted hazard ratios were estimated using conditional 
Cox regression (conditioned on the matching set with each set containing 1 surgery patient 
and up to 10 general population comparators). Robust confidence intervals were estimated 
and the proportional hazard assumption was evaluated by interacting time and treatment. 
 
 24 
3.3.4 Paper IV 
In this study, we retrospectively compared LRYGB patients operated at Danderyd Hospital 
with two different surgical methods (DM-LRYGB vs. IM-LRYGB), regarding postoperative 
anastomotic complications. The outcomes studied were leakage in the first 30 days and 
ulceration/stenosis in the anastomosis during the first 6 months. The data used in this study 
was gathered from the internal quality registry held at Danderyd Hospital. 
Differences in characteristics between the 2 groups were analyzed using the two-sample t-test 
or Pearson Chi2 test as appropriate. Failure curves were calculated using Kaplan-Meier 
estimates. Independent predictors of complications were identified and odds ratios (OR) 
calculated using multivariate logistic regression. The threshold for statistical significance was 
set to α<0.05 
STATA software was used for data management and all statistical calculation in paper I, II 
and IV. In study III some statistical analyses were performed using SAS (version 9.4).  
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4 RESULTS 
4.1 PAPER I 
A total of 11115 patients underwent a primary bariatric surgery with RYGB (37%) or a 
restrictive method (63%) during the study period 1980-2006. Restrictive methods included 
were VBG and GB surgery. The 2 groups had similar patient characteristics at baseline. The 
mean (SD) follow-up time was 3.8 (4.5) years for the RYGB cohort and 11.5 (6.0) years for 
the restrictive cohort.  
 
Preoperatively the patients in the gastric bypass cohort were more likely to have been 
diagnosed with substance abuse compared to the restrictive cohort. Postoperatively the risk 
for substance abuse, suicide attempt as well as alcohol abuse were significantly higher in the 
gastric bypass cohort. 
  
Tab 3. Preoperative IRR, and postoperative HRs of depression, substance abuse, suicide attempts and alcohol abuse 
for the RYGB cohort compared with the restrictive surgery cohort. Full table is found in paper I. 
Diagnosis Preoperative IRR (95% CI) Postoperative HR (95% CI) 
Alcohol abuse 1.1(0.8-1.4) 2.3 (1.7-3.2) 
Substance abuse 1.7 (1.2-2.5) 2.6 (1.7-5.0) 
Depression 1.1 (1.0-1.3) 1.3 (1.0-1.7) 
Suicide attempt 1.1 (1.0-1.4) 1.9 (1.4-2.5) 
IRR = Incidence Rate Ratio; HR = Hazard Ratio; RYGB = Roux-en-Y Gastric Bypass; CI = Confidence Interval 
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4.2 PAPER II 
A total of 16755 patients > 18 years old who underwent a primary RYGB surgery between 
1th Jan 2001 and 31 Dec 2010 were included in the analysis. The median follow-up time was 
1.9 (i.q.r. 0.83 – 3.76) years. Patients in the control group from the general population had 
higher education and higher socioeconomic status than patients in the RYGB surgery 
cohort. 
The RYGB cohort had a higher risk of diagnosis of substance abuse, depression and suicide 
attempt before surgery compared to the reference cohort from the general population. After 
surgery, this risk was higher in all groups, including alcohol abuse. 
 
Tab 4. Preoperative IRR and postoperative HR of depression, substance abuse, suicide attempts and alcohol 
abuse for the RYGB cohort compared with the reference cohort. Full table is found in paper II. 
Diagnosis Preoperative IRR (95% CI) Postoperative HR (95% CI) 
Alcohol abuse 1.13 (1.00-1.27) 2.73 (2.36-3.15) 
Substance abuse 1.80 (1.56-2.06) 3.17 (2.52-3.99) 
Depression 2.41 (2.25-2.58) 3.20 (2.81-3.65) 
Suicide attempt 2.00 (1.84-2.16) 2.85 (2.40-3.39) 
IRR = Incidence Rate Ratio; HR = Hazard Ratio; RYGB = Roux-en-Y Gastric Bypass  
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The prescription cohort is a subcohort that is comprised of 3139 RYGB patients from the 
main cohort. The cohort was selected so that all patients had 1-year preoperative data and 
4-year postoperative data from the PDR, the general characteristics in this cohort was 
similar to the main cohort. 
  
We found that patients in the RYGB cohort had more prescriptions of antidepressive 
medication, benzodiazepines and hypnotics before surgery. After surgery, the prescription 
of medication against alcohol dependence, benzodiazepines and hypnotics also increased in 
the surgery group, but not in the control group. The medication with antidepressants 
remained stable after surgery (Fig 9). 
 
Fig 9. Percentage of patients operated with Roux-en-Y gastric bypass (RYGB) surgery and control subjects 
who received at least one prescription each year for a alcohol dependence, b antidepressants, c 
benzodiazepines, and d hypnotic and sedatives in the year before surgery (year 0) and during a 4-year follow-
up interval after surgery. *P < 0.050 versus control group, †P<0.05 before versus after RYGB (Wald χ2 test). 
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4.3 PAPER III 
Diabetes treatment remission 
A total of 3629 patients with pharmacological treatment of type 2 diabetes in the year before 
surgery were included for analysis (mean age 49 years; 60.7% women; mean preoperative 
BMI 42.2) of remission. 
67% of the RYGB 
patients with diabetes 
treatment preoperatively 
were in remission of 
diabetes treatment 2 
years after surgery, and 
after 7 years of follow-up 
61% were without 
pharmacological diabetes 
treatment.  
 
 
 
Patients with a short 
duration (<2years) of 
diabetes treatment had a 
better chance of 
persistent treatment 
remission than patients 
with a longer duration 
of diabetes treatment 
(>2 years) during 7 
years of follow-up.  
 
Fig 10. Diabetes treatment before and after gastric bypass in patients with diabetes treatment the year before 
surgery in the (A) entire cohort and in (B) patients with < 2 years duration of diabetes treatment preoperative. 
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Diabetes treatment incidence 
A total of 18 418 patients without previous diabetes diagnosis, HbA1c<6.5% at baseline and 
no history of pharmacological treatment of type 2 diabetes were included for analysis (mean 
age 39 years; 78.8% women; mean preoperative BMI 42.7) of diabetes incidence. The group 
with comparators (matched for age and sex) from the general population were on average 
higher educated and had less medication for hyperlipidemia and hypertension. 
During a median follow-up of 4.6 years, there were 189 incident cases of pharmacological 
diabetes treatment in the total incidence cohort and 2319 in the matched general population 
comparators (21.4 vs. 27.9 cases per 10 000 person-years; adjusted hazard ratio 0.77 (95%CI 
0.67-0.89; P<0.001). 
For the subgroups that were compared with their own matched cohort from the general 
population the adjusted hazard ratios were 0.87 (95%CI 0.73-1.03; P=0.11) for patients with 
euglycemia and 0.62 (95%CI 0.48-0.80; P<0.001) for prediabetes. 
 
Fig 11. Cumulative incidence of diabetes treatment after gastric bypass, in patients without diabetes before 
surgery. Patients are divided by glycemic status at baseline and comparators are from the general population.  
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4.4 PAPER IV 
All patients treated with a primary antecolic Laparoscopic RYGB (LRYGB) at Danderyd 
Hospital from 2006 to June 30th 2015 were identified in the internal quality registry (n=2949).  
To minimize the effect of learning curve bias 329 patients operated by surgeons with less 
than 100 LRYGB procedures during this period were excluded from the analysis. 1116 of the 
patients had surgery between December 2006 and September 2010 with DM-LRYGB and 
1504 patients had surgery between November 2010 and June 2015 with the IM-LRYGB 
method. To further minimize the effect of learning curve bias the first 100 patients operated 
with each technique were also excluded prior to analysis, leaving 2420 patients included in 
the data analysis. 1016 of the included patients had surgery with DM-LRYGB and 1404 
patients had surgery with the IM-LRYGB method. 
Patients in the DM-LRYGB group were slightly older and had somewhat higher BMI, other 
baseline characteristics were similar (Table 5).  
The rate of GE leakage was reduced after the change of surgical technique, from 2.6% in the 
DM-LRYGB group to 1.1% in the IM-LRYGB group (p<0.05). The rate of stenosis or 
ulceration was significantly improved, from 5.6% in the DM-LRYGB group to 0.1% in the 
IM-LRYGB group (p<0.05). Adjusted Odds Ratio for leakage in the IM-LRYGB cohort 
compared to the DM-LRYGB cohort was 0.46 (95% CI 0.24-0.87), and for stenosis or 
ulceration the odds ratio was 0.01 (95% CI 0.002-0.09) 
Table 5. Results paper IV    
 DM-LRYGB 
(n=1016) 
IM-LRYGB 
(n=1404) 
P 
Leakage in the first 30 days (%) 2.6 1.1 P<0.05 
Odds Ratio Leakage (95% CI) IM-LRYGB vs. DM-
LRYGB 
 0.46 (0.24-0.87)  
Ulceration/Stenosis first 6 months (%) 5.6 0.1 P<0.05 
Odds Ratio Ulceration/Stenosis (95% CI) IM-LRYGB 
vs. DM-LRYGB 
 0.01 (0.002-0.09)  
General characteristics at baseline    
Women (%) 74.3 74.6  
Age (years); (mean (SD)) 43.0 (11.4) 41.7 (11.6)  
BMI (kg/m2); (mean (SD)) 42.1 (6.0) 39.4 (5.3)  
Operation time (minutes); (mean (SD)) 71.6 (25.2) 58.2 (20.0)  
Completed laparoscopic surgery (%) 98.2 99.3  
DM-LRYGB = Divided Mesentery Laparoscopic Roux-en-Y Gastric Bypass; IM-LRYGB = Intact Mesentery Laparoscopic 
Roux-en-Y Gastric Bypass; BMI = Body Mass Index; CI = Confidence Intervals; SD = Standard Deviations 
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5 DISCUSSION 
5.1 GENERAL ASPECTS 
Obesity is a major health problem in the world, involving also developing countries2. Modern 
society is driven by consumption of cheap processed food, fast food, soda, and candy that is 
marketed by companies. This, in conjunction with the fact that people perform less manual 
labor, results in an imbalance with increased calorie intake and reduced energy expenditure. 
Since obesity is mainly caused by modern life-style throughout the world, it is very hard to 
prevent, in fact there are almost no examples of preventive programs in any countries that has 
proven to be efficient. Life-style treatment programs and medical treatment lack long-term 
effect in most patients, and surgery has evolved as the most effective treatment in morbidly 
obese patients31,35. Historically bariatric surgery has been hampered by unacceptable rates of 
complications, but in the last decades with increased volumes of surgery, the surgical 
technique has been refined with laparoscopic surgery and some methods have been 
abandoned. Today the most common bariatric procedures are SG and RYGB, even if AGB is 
still performed in certain countries62. BPS/DS seems to be an alternative in some super obese 
patients57,60,170. The procedures have been refined and complications and perioperative 
mortality is today low44.  
Positive effects of surgery are well established, and the effects on weight loss, diabetes and 
other comorbid diseases are way superior compared to other available treatments. Most 
people, even bariatric surgeons, probably realize that treating conditions that really are caused 
by life-style problems in society with surgery is not the ideal long-term solution. Ideally, we 
would need to prevent the epidemic of obesity by radical changes in physical activity from 
school age and by promoting healthy diets, possibly by applying special taxes on unhealthy 
food or other drastic measures. This is for obvious reasons not easily done. Effective life-style 
treatment programs in obese patients would also be an attractive option, but even if some 
studies can show some effect on long-term weight-loss, results are disappointing when 
compared to surgery34. Those intensive treatment programs also require significant resources 
to be successful with continuous contacts over several years. In patients where life-style 
intervention programs are not effective, pharmacological treatment would also be an 
attractive option. However, the pharmacological treatments available today all have inferior 
effect on weight loss compared to bariatric surgery, and the side effects of the medications are 
sometimes problematic37. Effective pharmacological treatment against obesity would be a 
gold mine for pharmacological companies, and lots of resources are likely to be invested in 
this research in the future. Bariatric surgery might play a role in the development of new 
pharmacological treatments as we today know that the weight loss and effect on diabetes seen 
after gastric bypass is more complex than just a reduction of calorie intake and uptake. In 
fact, we still don´t know the exact mechanisms. With further progress in research on the 
physiological alterations after RYGB, new pharmacological treatments might evolve.  
Until we can manage to prevent obesity or treat obesity with effective non-surgical 
treatments, bariatric surgery will continue to play an important role in the global war against 
the obesity epidemic. It is today undisputed that bariatric surgery is very effective, what we 
need to know more about is which procedures produces the best long-term results, in 
combination with low complication rates. The procedures in use can also be refined to even 
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further reduce complications. Another important issue is to know more about which patients 
are suitable, and not suitable, for surgery and when surgery should be considered.   
The focus of this thesis was to investigate not only the positive effects of gastric bypass 
surgery but also at some possible negative health effects of surgery, and to add information 
valuable for the selection of patients for surgery. The more specific topics in this thesis will 
be further discussed in the next sections. 
5.2 DIABETES 
In paper III we linked SOReg data with the PDR to get full information on prescribed drugs 
in patients operated with RYGB between 2007 and 2012. We show that 67% of patients with 
diabetes treatment before surgery were in remission of diabetes treatment after 2 years, and 
that 61% of patients were still in remission at 7 years follow-up. These are remission rates in 
line with earlier studies, but this study add strength to the existing literature in the way that it 
is a nationwide study with almost complete follow-up of up to 7-years, since all prescribed 
drugs in Sweden are found in the PDR. Another strength is that only RYGB patients are 
included in this study, compared to some other studies that have a mix of surgical treatments. 
We also show that in patients with a short duration (< 2 years) of diabetes treatment the 
effects were even more remarkable with remission of diabetes treatment of 88 % at 2 years 
and 86 % at 7 years follow-up. RYGB is not only effective in the treatment of diabetes, it also 
seems to prevent against new cases of diabetes in obese patients. Previous studies have 
compared bariatric surgery patients without diabetes to an obese control group and 
demonstrated that that surgery is preventive against new cases of diabetes in obese 
patients95,171. In fact, we show in paper III that even patients with prediabetes at baseline have 
lower risk for diabetes treatment after surgery, compared to a control group from the general 
population. The control group in our study was not matched for weight or glycemic status 
since it was not available. The results from this study indicate that patients with diabetes have 
an effective long-term result on their diabetes. It also demonstrates that patients should be 
considered for surgery early after their diabetes debut, or even already when prediabetes is 
present. Even in cases with persistent diabetes treatment after surgery we demonstrate that 
more than 50% of patients with insulin treatment preoperative manage without insulin at least 
7 years after surgery. 
RYGB has a positive effect on diabetes even in patients with mild obesity32. A joint statement 
from international diabetes organizations in 2016 stated that surgery was recommended to 
treat type 2 diabetes in patients with obesity grade III (BMI>40), and in those with grade II 
obesity (BMI 35.0–39.9) when diabetes is inadequately controlled by lifestyle and optimal 
medical therapy. The same statement also declared that surgery should be considered for 
patients with type 2 diabetes and BMI 30.0–34.9 if hyperglycemia is inadequately 
controlled despite optimal treatment with either oral or injectable medications 172. 
In fact, several studies have been performed with good effect on diabetes also in non-obese 
patients (BMI <30), even if the effect is not as obvious as in obese patients103,173. Today this 
surgery is only performed within research projects and the consensus is that further evidence 
is needed before recommending it to non-obese patients. However, based on present 
knowledge, it is possible that RYGB, SG or some further developed method of surgery, will 
be a recommended treatment option in non-obese patients with drug refractory diabetes type 
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2, when more long-term data exists.  
Prediabetes is a condition that untreated will lead to diabetes in most patients. In a 45-year 
old patient with prediabetes, the lifetime risk of developing diabetes has been estimated to be 
74% 174. In patients with BMI<40 and prediabetes it is reasonable to start with lifestyle 
interventions. Studies on patients with prediabetes have shown that development of diabetes 
can be successfully intervened, or at least delayed, even with moderate weight-loss28,175. 
Liraglutide could also be an option in some of those patients, in addition to dietary change 
and physical activity. Liraglutide has proven effects on prediabetes and weight-loss, even if 
the effects are moderate especially regarding weight-loss and the treatment is expensive and 
requires daily injections 39. Patients with prediabetes should be closely monitored, and if 
conservative interventions fail to produce weight-loss, or if the patients develop diabetes, 
surgery should be recommended early as demonstrated by the results in paper III in this 
thesis. In severely obese patients with prediabetes, my opinion is that bariatric surgery should 
be recommended. 
5.3 PSYCHIATRY, ALCOHOL AND SUBSTANCE ABUSE 
Some early reports indicated that there might be an increased risk for alcohol abuse after 
gastric bypass surgery, otherwise not much was known on this topic at the start of this thesis 
project. Studies had also shown that the risk for suicide and attempted suicide was elevated in 
bariatric surgery patients after surgery112. In papers I and II we used the Swedish NPR to 
examine if gastric bypass surgery patients have more inpatient care diagnosis of alcohol 
abuse, substance abuse, depression or suicide attempts, before and after surgery, compared to 
restrictive surgery patients (paper I) and general population controls (paper II). In paper I we 
compared patients operated with RYGB, with patients operated by restrictive procedures, 
more exactly VBG or GB. We found that RYGB patients had higher postoperative risk for 
diagnosis of alcohol abuse and attempted suicides compared with restrictive surgery patients. 
This might be caused by the altered metabolism of alcohol seen after RYGB158,159,176, but not 
after restrictive procedures, leading to higher ethanol concentrations in the blood. Alcohol is 
degraded partly in the gastric mucosa by alcohol dehydrogenase and after RYGB a large 
proportion of the gastric mucosa is bypassed and also the emptying of the gastric pouch is 
quicker after RYGB160.  This leads to higher peak alcohol concentrations, which could be one 
factor that stimulates alcohol related problems. Another finding in paper II suggesting that 
alcohol related problems are more common after RYGB surgery is that the prescription of 
medication against alcohol abuse increases significantly after surgery. Prescriptions of 
benzodiazepines, sedatives and hypnotics also increase after surgery. There are no indications 
that patients have more anxiety or sleeping disorders after surgery, thus increased 
prescriptions could indicate a substance abuse problem. Since we don´t know the exact 
reasons for the prescriptions we cannot draw any conclusions, but the findings indicate that 
this should be investigated further. There are other studies that present increased substance 
abuse after surgery153,177. Papers I and II provide an important addition to previously existing 
literature because of the large cohort with good follow up, whereas some previous studies 
were small and had problems with incomplete follow-up. Today we can say that the existing 
literature shows that alcohol related problems, accidents, as well as suicide and suicide 
attempts increases after RYGB surgery150,178. There might be an association of these factors 
since alcohol abuse increases the risk for accidents and suicide.  
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Patients need to be educated of this problem before surgery. Patients with suspected ongoing 
alcohol or substance abuse should not undergo RYGB surgery, not only because the alcohol 
abuse can be worsened, but also as patients must adhere to given instructions for food and 
vitamin intake after surgery. In worst case Wernicke’s encephalopathy has been described179. 
In patients with a history of problematic alcohol use, other bariatric surgery methods than 
RYGB should be considered to reduce the risk of postoperative alcohol abuse. These patients 
also require closer monitoring and counseling in the postoperative period.  
In paper II we demonstrate that there is no reduction in prescriptions of antidepressants or 
inpatient care diagnosis of depression after surgery. About 30% of patients are on anti-
depressive treatment preoperative, and some patients expect surgery to be the solution to all 
their psychological problems. Even if overall HRQoL is improved after surgery, it is mostly 
in the physical aspect, whereas long-term benefits in psychosocial QoL remain uncertain 117 . 
This must be communicated to the patients before surgery, to avoid unrealistic expectations.  
 
5.4 COMPLICATIONS 
As mentioned in the introduction, the most common complications after surgery are bleeding, 
internal hernias, small bowel obstruction, leakage, ulceration and stenosis in the anastomosis. 
There are also general complications such as urinal infections, deep vein thrombosis, and 
infections as in all larger surgical procedure. Other negative effects of surgery that can´t be 
related to a specific complication are for example problem with dumping, chronic abdominal 
pain and extreme skin excess. Complications and postoperative morbidity have been reduced 
with the introduction of laparoscopic technique and improved perioperative care. Increased 
surgical volumes has probably also helped to reduce complications.  
Technical refinements can reduce complications after RYGB, for example linear stapling 
reduces the risk for stenosis 123,180, closure of mesenteric defects reduces the risk for IH 143, 
laparoscopic surgery decreases the risk for wound complications and use of PPI reduces the 
risk for marginal ulcer 133. Further refinements will continue to evolve. In paper IV we 
compare two different techniques of RYGB, regarding postoperative complications. At 
Danderyd hospital, we changed our technique in 2010 from the classic RYGB with divided 
mesentery, to a technique where the mesentery is left intact. This was done since we had high 
complication rates compared to other centers in Sweden, already using the intact mesentery 
method, according to SOReg. In paper IV we present a significant reduction of leakage and 
ulceration/stenosis in the anastomosis at our clinic, after alteration of the technique. Our 
theory behind this is that the circulation to the anastomosis is compromised when the 
mesentery is divided, leading to ischemic ulceration and stenosis. This is not farfetched, since 
mucosal stapling itself leads to mucosal ischemia181. Division of the mesentery, which 
supplies blood to the intestine, might very well enhance this ischemia. Ulceration and stenosis 
is investigated as one entity in our study, because we think that they are correlated and caused 
partly by the same mechanisms. When routine endoscopy is performed in patients after 
RYGB, 12% have marginal ulceration after 1 month, and in patients with marginal ulcer 40% 
have some grade of stenosis at the same time130. This could indicate that stenosis is the result 
of an ulcer, healing with fibrosis. Even if our study has some obvious weaknesses, discussed 
  35 
in the limitation section, we think that our study strongly indicates that RYGB should be 
performed without division of the mesentery to reduce complications. However, a 
randomized study is needed to definitely prove this.  
Surgeons performing RYGB surgery, and other bariatric surgery, need to stay curious and 
updated on new techniques and follow their patients regarding postoperative complications. 
The ambition must be to further evolve existing and new techniques to reduce complications 
for the benefit of the patients. 
 
5.5  LIMITATIONS 
5.5.1 General limitations 
All studies in this thesis are of retrospective character, based on data from different registries. 
Swedish registries are generally of good quality, but data is not stored for the intention of 
specific research projects. Even if they have a completion rate of almost 100% for every 
hospital stay or visit in the outpatient clinic, the diagnosis stored is not always the correct one, 
or some secondary diagnosis might be missed. If data is not stored correctly the results of the 
studies will be affected. This might differ between different diagnoses; for example, diabetes 
is probably more correctly diagnosed than alcohol and substance abuse. The data from the 
registries will not in any way be exactly correct, but in a comparison with a control group it is 
probably valid since misdiagnosing will be performed equally in the study group and in the 
control group. 
5.5.2 Limitations Papers I and II 
Except for the general limitations of registry studies, there are some other limitations of these 
studies. In paper I we compare patients operated with different methods, popular during 
different periods. Patients operated with restrictive procedures are generally operated earlier 
than patients operated with RYGB, thus leading to longer follow-up in the patients operated 
with restrictive procedures. Even if the Cox regression model should deal with this, it might 
affect the result to some degree. We also know that postoperative complications have been 
reduced over the years, even if this hardly affects the results of this study in any significant 
way.  
In both studies, we only analyze inpatient diagnosis of depression, suicide attempt, alcohol 
and substance abuse, meaning that patients diagnosed only in the outpatient clinic is not 
detected. For depression, alcohol abuse and substance abuse we can assume that a significant 
number of patients are missed because of this, but the comparison between the groups 
regarding inpatient diagnosis are still valid since this will affect both groups equally. 
There is also a potential of follow-up bias since patients undergoing surgery is more likely to 
be in contact with healthcare during routine follow-up or because of complications. If patients 
are in contact with healthcare, other problems are more likely to be diagnosed as well. 
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5.5.3 Limitations paper III 
In the study of diabetes remission, we lack glycemic status during follow-up in both the 
surgery and population control group, thus relying only on diabetes treatment as an indication 
of patients’ diabetes status. Some patients probably go with untreated diabetes, even if we can 
assume that patients with previous diabetes have some kind of long-term follow-up. 
In the study of diabetes incidence, we also lack glycemic status and weight in the general 
population controls. This means that some individuals in the general population probably will 
have undiagnosed diabetes or prediabetes at baseline, whereas in the surgery cohort the 
patients are screened and no patients have diabetes at baseline. 
5.5.4 Limitations paper IV 
There are several limitations in paper IV. Firstly, the retrospective character of the study with 
patients operated during different time frames makes the groups somewhat hard to compare 
since we know that complications are generally decreasing after bariatric surgery. There is an 
issue with potential learning curve bias, even if we tried to reduce this by eliminating the first 
100 patients in both groups, as well as patients operated by a surgeon with less than 100 total 
procedures. Unfortunately, we also extended our postoperative PPI treatment from 1-month 
to 3-months at the same time as we changed surgical technique and this probably also affect 
the results on ulceration/stenosis. 
Another issue is that we only use data from our internal quality registry at Danderyd. If a 
patient was treated elsewhere for complications it would not be detected in our registry. In 
Stockholm, there is consensus that each clinic takes care of its own complications, reducing 
the risk for this. However, some of the patients are patients from other regions in Sweden and 
they are more likely to be treated at their regional hospital, especially for ulceration/stenosis, 
which is most often diagnosed after patients leave hospital. Ulceration and stenosis is to a 
higher degree treated by endoscopic interventions and medicine, which might be taken care 
of at a regional hospital.  
5.6 FUTURE OF BARIATRIC SURGERY 
Bariatric surgery will probably continue to be the most effective treatment for morbid obesity 
in the near future. SG has lately become an alternative to the RYGB, but long-term effects are 
still not evaluated. We know that patients operated with SG have slightly inferior effect on 
weight-loss and comorbidities, but also slightly fewer complications than RYGB 
patients90,93,182-187. Based on the experience from earlier gastroplasties, they tend to have a 
good initial effect but regain weight in the long-term. Some studies are starting to report 5-
year follow up after SG and the tendency with weight-regain is seen also in the SG 
patients188. Patients, wishing for a simpler operation, largely drive the trend to more SG 
procedures. Short-term results after SG are comparable to RYGB and this brings a good 
reputation among patients. The BEST study is an ongoing randomized multicenter study in 
Sweden, randomizing patients between RYGB and SG. Long-term data from this study will 
hopefully help us, and our patients, to choose the most suitable procedure in the future. 
Based on current knowledge it is possible that bariatric surgery will be used to treat diabetes 
type 2 also in non-obese patients in cases of drug refractory diabetes, when more long-term 
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data from studies exist. New surgical methods with even lower complication rates would also 
lower the threshold for surgery in patients with diabetes.  
We will need better tools to decide which procedure is best for the individual patient. Patients 
with different behavior patterns, e.g. drinking and eating behaviors, could be better suited for 
different surgical procedures. Patients must also be informed about potential negative health 
effects and patients with a history of problematic alcohol use should be advised to have other 
bariatric surgery than RYGB.   
From what we know today RYGB should probably be the first choice procedure for most 
patients, because of well-known long-term effect and reasonably low complication rates. 
Recent studies favor closure of the mesenteric defects to reduce internal hernias even if early 
complications slightly increase143. RYGB should also be performed without division of the 
mesentery to reduce complications, as shown in paper III, and prolonged PPI treatment for 
3months is also advisable. SG seem to be the alternative, at least in patients with a BMI <40 
without comorbidities, with the advantages of a simpler operation and no risk for internal 
hernias, but long-term effects need to be evaluated further. 
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6 CONCLUSIONS 
RYGB is a safe operation with remarkable effects on diabetes type 2 treatment in obese 
patients. Treatment with RYGB should be considered in an early stage of diabetes to get the 
best effect. It also prevents future treatment of diabetes in obese patients with prediabetes. 
RYGB increases the risk for diagnosis of alcohol use disorders and suicide attempts, patients 
have increased prescriptions of benzodiazepines, hypnotics and drugs against alcohol abuse 
after surgery. RYGB does not lead to a reduction of inpatient diagnosis of depression or 
reduced antidepressive treatment. 
RYGB should be performed with the intact mesentery technique to reduce complications in 
the anastomosis. 
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